Oral versions are in development, and if they work, thats a game changer
Overall, the prevalence of coverage in the individual market is very low but not nonexistent and is more prevalent in states that have their own insurance exchange
However, many patients still have important questions regarding eligibility requirements, treatment timelines, provider oversight, potential side effects, medication costs, and the differences between semaglutide and tirzepatide
Recent research demonstrates that Retatrutide (a triple agonist) significantly suppresses microglial nitrite production, TNF- release, and COX2 expression in LPS-activated microglia, outperforming single GLP-1R agonists like exendin-4 [37]
They are part of a rapidly evolving landscape of research peptides being studied for metabolic, body composition, and systemic health applications
GLP-1 drugs show promise for weight management Across the reviewed studies, tirzepatide, semaglutide, and liraglutide consistently led to significant weight loss over one to two years compared with placebo, and the benefits appeared to continue during ongoing treatment
